Hematology
Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.
Recent Discussions
How do you counsel patients on VTE prevention during prolonged travel (≥4 hours), and how does your approach differ based on individual VTE risk factors (e.g., obesity, active cancer, prior VTE)?
I use travel guidance/patient handouts from stoptheclot.org for patients with low-risk interventions, such as staying hydrated, wearing compression socks, and in-flight seated exercises. I do not routinely recommend prophylactic anticoagulation in patients who are not otherwise on prophylactic antic...
How do you manage patients with HHT who have AFib with risk factors for stroke and who require anticoagulation?
Patients with HHT may tolerate therapeutic anticoagulation, and we therefore generally trial anticoagulation in patients with atrial fibrillation who have an elevated stroke risk (Faughnan et al., PMID 32894695). Available data suggest that warfarin may be better tolerated than direct oral anticoagu...
What would be your preferred anticoagulant for recurrent DVT/PE in a patient on hemodialysis with calciphylaxis and prior DOAC failure?
A truly complex case: recurrent DVT/PE in the setting of ongoing risk factors for both VTE (active calciphylaxis, prior DOAC failure, and obesity) and bleeding (ESRD on hemodialysis), each of which constrains a different anticoagulant option. Given the complexity and rarity of this case, recommendat...
When would you use AVD + brentuximab instead of ABVD for newly diagnosed stage 3 or 4 Hodgkin lymphoma?
By reducing the risk of primary treatment failure from 23% to 18%, the ECHELON-1 study demonstrated that compared to ABVD, AVD + brentuximab vedotin reduces the risk of primary treatment failure by about 25% for patients with advanced-stage classic Hodgkin lymphoma. If given with prophylactic G-CSF,...
Would you consider starting myeloma treatment in a patient with detectable monoclonal protein, non-FDG avid lytic bone lesions, and bone marrow clonal plasma cells <10%?
The presence of lytic lesions should be considered diagnostic of myeloma and FDG uptake is not mandatory for making a diagnosis. While diagnostic criteria require 10% plasma cells, these should be interpreted in the clinical context, and in a patient with lytic lesions that are consistent with myelo...
How does your approach to subsegmental PE differ from segmental PE both diagnostically and therapeutically?
My approach to subsegmental PE and segmental PE generally tends to be very similar. I am aware of the CHEST guidelines which indicate patients can safely be observed with subsegmental PE, but like a recent study showed (Rouleau et al., PMID 37531107), uptake of these guidelines is slow and many pati...
What factors do you consider before discharging an MGUS patient from hematology clinic to safely follow with outpatient PCP?
In general, I follow the risk stratification referenced in the Mayo Clinic's recent review, and I tend to think about a clinic discharge from hematology if they have low-risk MGUS, i.e., serum M protein <1.5 gm/dL, IgG subtype, normal FLC ratio (0.26-1.65).I then use the Lee Index to estimate the pa...
What is your approach to chronic non-immune mediated thrombocytopenia management in children?
There are whole textbook chapters on this topic, and we use a variant of this question to review the differential diagnosis of thrombocytopenia with our fellows as a didactic exercise. So I take from this question, which is an important one, what might be a framework to consider the differential dx ...
Would you stop current immunosuppressive therapy or delay starting immunosuppressive therapy in a patient with aplastic anemia who has been infected with COVID-19?
Not much is known yet about this specific situation—but our growing experience here in New York City suggests it may be safe. We have had several post-BMT patients who were on immune suppression for GVHD become COVID positive who have not had significant problems. Also, we have now treated 8-10 pat...
How do you approach a patient with IgM monoclonal gammopathy associated with severe neuropathy of unclear etiology?
I usually confirm if the patient does not have AL Amyloidosis or POEMS, and as part of work up for IgM MGUS, I order MYD 88 mutation. If all are negative and I still believe that neuropathy is caused from his/her MGUS, you can try IVIG for the neuropathy as a trial (of course after using gabapentin,...